It’s the future of liquid biopsy: For the first time, diagnostics can be built around cell- and exosome-based assays on the same LiquidScan™ instrument for cancer screening and prenatal testing.
LiquidScan™ combines cutting-edge microfluidics, advanced immunoaffinity chemistries, automation hardware, and workflow optimization to put liquid biopsy within easier reach for precision medicine for multiple cancers and prenatal diagnostics testing.
THE FUTURE OF LIQUID BIOPSY
BioFluidica LiquidScan™ isolates and enriches rare cells and exosomes from liquid biopsy samples. LiquidScan™ can enrich CTCs or fetal cells from whole blood and exosomes from plasma enabling cell-based liquid biopsy analyses.
LEARN MORE ABOUT US
RECENT BIOFLUIDICA NEWS
BioFluidica Will Exhibit at AACR 2023, Orlando, FL April 14-19th – Come See Us!
The American Association for Cancer Research, AACR, will hold their [Read More...]
HER2+ Breast Cancer Pilot Study
February 9, 2023 Blood was drawn from [Read More...]
BioFluidica Exhibits and Presents at PMWC 2023 in Santa Clara, CA
February 9, 2023 BioFluidica attended the Precision [Read More...]